Summary
Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. Its principle toxicity is myelosuppression. We conducted a phase I trial using AZQ in combination with GM-CSF to determine if the maximal tolerated dose (MTD) of AZQ could be escalated. Using GM-CSF on a standard schedule, we were unable to escalate the previously determined MTD of diaziquone with the use of this colony stimulating factor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kahn AH, Driscoll JS: Potential central nervous system antitumor agents. Aziridnylbenzoquinones. J Med Chem 19:313–317, 1976
Friedman JS, Schold SC, Varia M: Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice. Cancer Res 43:3088–3093, 1983
Eagan RT, Dinapoli RP, Cascino TL, Scheithauer B, O'Neill BP, O'Fallon J: Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors. J Neuro Oncol 5:309–314, 1987
Chamberlain MC, Prados MD, Silver P, Levin VA: A phase I/II study of 24-hour intravenous AZQ in recurrent primary brain tumors. J Neuro Oncol 6:319–323, 1988
Kelley JA, Siu Chong ED: Reverse phase HPLC determination of AZQ in biological fluids. J Liq Chromatogr 4:1855–1867, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hartmann, L.C., Ames, M.M., Reid, J.M. et al. Phase I trial of diaziquone (AZQ) plus GM-CSF. Invest New Drugs 13, 175–176 (1995). https://doi.org/10.1007/BF00872869
Issue Date:
DOI: https://doi.org/10.1007/BF00872869